Discuss the strategic deployment of European litigation venues for US pharma companies, including the UK High Court litigation, UPC proceedings and EPO
9
All information is kept strictly confidential. Please do not distribute.
Please contact: [email protected] for further information.
oppositions, and compare the impacts on injunction risk, cost exposure, and global settlement dynamics.
Speaker(s):

Oliver Laing
Partner
Potter Clarkson

Mark Didmon
Partner
Potter & Clarkson
Agenda Track No.:
Track 3
Session Type:
Break / Networking
Force Inline Description:
0